Raymond James lowers Welltower stock price target on valuation

Raymond James cut its Welltower price target to $263 from $270 but maintained Outperform, raising its 2026 FFO estimate by over 1% to $6.52 per share and its 2027–2028 estimates by 3%–4%, to $7.73 and $8.93. Welltower’s Q3 2026 EPS of $0.54 missed the $0.65 forecast, while revenue of $3.72 billion exceeded the $3.66 billion estimate; the company raised its full-year FFO outlook. Normalized FFO per diluted share rose 24.6% to $1.67 and same-store NOI increased 15.8%; Welltower also filed for potential issuance of up to 1,648,490 common shares.

Analysis

The key tension is operating momentum versus the price paid for it. For a REIT, the cited P/E is a poor standalone valuation anchor; the decision should turn on price/FFO or AFFO, NAV premium, and whether incremental acquisitions earn returns above Welltower’s cost of capital. A premium-funded roll-up can widen its advantage over smaller senior-housing operators, but only while acquisition yields, occupancy and operating margins hold up. If asset pricing tightens or labor and operating costs absorb rent gains, growth in portfolio NOI may not translate into comparable per-share FFO growth.

Near term, elevated expectations and a strong prior share-price run leave room for multiple compression even if operations remain sound; the analyst estimate increases are not evidence that consensus has reset enough. Over 1–3 months, track same-store occupancy and NOI, per-share FFO guidance, acquisition yields versus financing costs, and actual issuance/share-count changes. The prospectus supplements are a dilution watch, not proof of material dilution: assess any issuance against shares outstanding and incremental FFO. Over 6–18 months, senior-housing demand may support rent and occupancy, but execution and acquisition discipline determine whether that becomes durable per-share value. A thesis of continued premium performance weakens if guidance or same-store trends decelerate, or acquisition returns fall below funding costs.

Key Decisions for Investors

• Do not chase the recent rally on estimate revisions alone. Reassess entry using price/FFO or AFFO and NAV premium; the bullish case needs sustained occupancy and same-store NOI growth to support the valuation.
• Keep WELL on a relative-value watchlist rather than initiate an outright short now: operating momentum is a meaningful offset to valuation risk. Consider a short-versus-healthcare-REIT-basket expression only if WELL’s valuation premium widens while per-share FFO revisions or operating indicators roll over.
• Monitor subsequent filings for shares actually issued and compare dilution with incremental FFO. Treat issuance as thesis-negative only if share growth outpaces per-share operating improvement; the disclosed potential issuance alone is insufficient to establish material dilution.
• Falsification checks: a downward FFO-guidance revision, slowing same-store occupancy/NOI, or acquisition yields no longer covering funding costs would undermine the growth thesis; sustained per-share growth without those deteriorations would argue against fading the premium.